Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice

Clinical Immunology

Volumn 154, Issue 1, 2014, Pages 26-36

  Zhang, Yufei ^a   Luo, Feifei ^a   Li, Anning ^b   Qian, Jiawen ^a   Yao, Zhenwei ^b   Feng, Xiaoyuan ^b   Chu, Yiwei ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Adoptive T cell therapy; Bacterial lipoprotein; Glioma; Toll like receptor 2; Tumor microenvironment

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM LIPOPROTEIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIPOPROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; GLIOMA; LONG TERM SURVIVAL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; T LYMPHOCYTE; THERAPY EFFECT; TUMOR MICROENVIRONMENT; UPREGULATION;

ADOPTIVE T CELL THERAPY;; BACTERIAL LIPOPROTEIN;; GLIOMA;; TOLL-LIKE RECEPTOR 2;; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SURVIVAL; CELL- AND TISSUE-BASED THERAPY; FEMALE; FLOW CYTOMETRY; GLIOMA; IMMUNOTHERAPY, ADOPTIVE; LIPOPROTEINS; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2;

EID: 84903768671     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.06.004     Document Type: Article

References (49)

1. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
2. Wrensch M., Minn Y., Chew T., Bondy M., Berger M.S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 2002, 4:278-299.
3. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O., European Organisation for R., Treatment of Cancer Brain T., Radiation Oncology G., National Cancer Institute of Canada Clinical Trials G. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
4. Kochenderfer J.N., Wilson W.H., Janik J.E., Dudley M.E., Stetler-Stevenson M., Feldman S.A., Maric I., Raffeld M., Nathan D.A., Lanier B.J., Morgan R.A., Rosenberg S.A. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
5. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., Kammula U.S., Hughes M.S., Restifo N.P., Raffeld M., Lee C.C., Levy C.L., Li Y.F., El-Gamil M., Schwarz S.L., Laurencot C., Rosenberg S.A. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 2011, 29:917-924.
6. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., Morton K.E., Laurencot C.M., Steinberg S.M., White D.E., Dudley M.E. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 2011, 17:4550-4557.
7. Okada H., Kalinski P., Ueda R., Hoji A., Kohanbash G., Donegan T.E., Mintz A.H., Engh J.A., Bartlett D.L., Brown C.K., Zeh H., Holtzman M.P., Reinhart T.A., Whiteside T.L., Butterfield L.H., Hamilton R.L., Potter D.M., Pollack I.F., Salazar A.M., Lieberman F.S. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethyl cellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 2011, 29:330-336.
8. Kohanbash G., Okada H. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol. Investig. 2012, 41:658-679.
9. Walker P.R., Calzascia T., de Tribolet N., Dietrich P.Y. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res. Brain Res. Rev. 2003, 42:97-122.
10. Walker P.R., Dietrich P.Y. Immune escape of gliomas. Prog. Brain Res. 2001, 132:685-698.
11. Takeda K., Kaisho T., Akira S. Toll-like receptors. Annu. Rev. Immunol. 2003, 21:335-376.
12. Liew F.Y., Xu D., Brint E.K., O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 2005, 5:446-458.
13. Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22:240-273. (Table of Contents).
14. Hajishengallis G., Lambris J.D. Microbial manipulation of receptor crosstalk in innate immunity. Nat. Rev. Immunol. 2011, 11:187-200.
15. El Andaloussi A., Sonabend A.M., Han Y., Lesniak M.S. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006, 54:526-535.
16. Chicoine M.R., Zahner M., Won E.K., Kalra R.R., Kitamura T., Perry A., Higashikubo R. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 2007, 60:372-380. (discussion 381).
17. Caron G., Duluc D., Fremaux I., Jeannin P., David C., Gascan H., Delneste Y. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J. Immunol. 2005, 175:1551-1557.
18. Cottalorda A., Verschelde C., Marcais A., Tomkowiak M., Musette P., Uematsu S., Akira S., Marvel J., Bonnefoy-Berard N. TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur. J. Immunol. 2006, 36:1684-1693.
19. Gelman A.E., Zhang J., Choi Y., Turka L.A. Toll-like receptor ligands directly promote activated CD4+ T cell survival. J. Immunol. 2004, 172:6065-6073.
20. Komai-Koma M., Jones L., Ogg G.S., Xu D., Liew F.Y. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3029-3034.
21. Zhang Y., Luo F., Cai Y., Liu N., Wang L., Xu D., Chu Y. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J. Immunol. 2011, 186:1963-1969.
22. Ciesielski M.J., Ahluwalia M.S., Munich S.A., Orton M., Barone T., Chanan-Khan A., Fenstermaker R.A. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol. Immunother. 2010, 59:1211-1221.
23. Pino P.A., Cardona A.E. Isolation of brain and spinal cord mononuclear cells using percoll gradients. J. Vis. Exp. 2011.
24. Sun X., Zhang Q.W., Xu M., Guo J.J., Shen S.W., Wang Y.Q., Sun F.Y. New striatal neurons form projections to substantia nigra in adult rat brain after stroke. Neurobiol. Dis. 2012, 45:601-609.
25. Cao L.F., Krymskaya L., Tran V., Mi S., Jensen M.C., Blanchard S., Kalos M. Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis. Cytometry A 2010, 77:534-545.
26. Kalos M., June C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013, 39:49-60.
27. Kershaw M.H., Westwood J.A., Parker L.L., Wang G., Eshhar Z., Mavroukakis S.A., White D.E., Wunderlich J.R., Canevari S., Rogers-Freezer L., Chen C.C., Yang J.C., Rosenberg S.A., Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
28. Alizadeh D., Zhang L., Brown C.E., Farrukh O., Jensen M.C., Badie B. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin. Cancer Res. 2010, 16:3399-3408.
29. Fujita M., Kohanbash G., Fellows-Mayle W., Hamilton R.L., Komohara Y., Decker S.A., Ohlfest J.R., Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011, 71:2664-2674.
30. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.M., Feng Z.H. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett. 2007, 252:86-92.
31. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 2012, 12:269-281.
32. Albesiano E., Han J.E., Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg. Clin. N. Am. 2010, 21:17-29.
33. Facoetti A., Nano R., Zelini P., Morbini P., Benericetti E., Ceroni M., Campoli M., Ferrone S. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin. Cancer Res. 2005, 11:8304-8311.
34. Gustafson M.P., Lin Y., New K.C., Bulur P.A., O'Neill B.P., Gastineau D.A., Dietz A.B. Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncology 2010, 12:631-644.
35. Asprodites N., Zheng L., Geng D., Velasco-Gonzalez C., Sanchez-Perez L., Davila E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J. 2008, 22:3628-3637.
36. Murata M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci. 2008, 99:1435-1440.
37. Schneider C., Schmidt T., Ziske C., Tiemann K., Lee K.M., Uhlinsky V., Behrens P., Sauerbruch T., Schmidt-Wolf I.G., Muhlradt P.F., Schmidt J., Marten A. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004, 53:355-361.
38. Seif A.E., Barrett D.M., Milone M., Brown V.I., Grupp S.A., Reid G.S. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood 2009, 114:2459-2466.
39. Galli R., Starace D., Busa R., Angelini D.F., Paone A., De Cesaris P., Filippini A., Sette C., Battistini L., Ziparo E., Riccioli A. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J. Immunol. 2010, 184:6658-6669.
40. Grauer O.M., Molling J.W., Bennink E., Toonen L.W., Sutmuller R.P., Nierkens S., Adema G.J. TLR ligands in the local treatment of established intracerebral murine gliomas. J. Immunol. 2008, 181:6720-6729.
41. Li Q., Lao X., Pan Q., Ning N., Yet J., Xu Y., Li S., Chang A.E. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin. Cancer Res. 2011, 17:4987-4995.
42. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 2007, 13:552-559.
43. Liang J., Fu J., Kang H., Lin J., Yu Q., Yang Q. The stimulatory effect of TLRs ligands on maturation of chicken bone marrow-derived dendritic cells. Vet. Immunol. Immunopathol. 2013, 155:205-210.
44. Zhang H., Chua K.S., Guimond M., Kapoor V., Brown M.V., Fleisher T.A., Long L.M., Bernstein D., Hill B.J., Douek D.C., Berzofsky J.A., Carter C.S., Read E.J., Helman L.J., Mackall C.L. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. 2005, 11:1238-1243.
45. Fukui A., Ohta K., Nishi H., Shigeishi H., Tobiume K., Takechi M., Kamata N. Interleukin-8 and CXCL10 expression in oral keratinocytes and fibroblasts via Toll-like receptors. Microbiol. Immunol. 2013, 57:198-206.
46. Imaizumi T., Murakami K., Ohta K., Seki H., Matsumiya T., Meng P., Hayakari R., Xing F., Aizawa-Yashiro T., Tatsuta T., Yoshida H., Kijima H. MDA5 and ISG56 mediate CXCL10 expression induced by toll-like receptor 4 activation in U373MG human astrocytoma cells. Neurosci. Res. 2013, 76:195-206.
47. Li N., Quidgley M.C., Kobeissy F.H., Joseph J., Neu J. Microbial cell components induced tolerance to flagellin-stimulated inflammation through Toll-like receptor pathways in intestinal epithelial cells. Cytokine 2012, 60:806-811.
48. Aravalli R.N., Hu S., Woods J.P., Lokensgard J.R. Histoplasma capsulatum yeast phase-specific protein Yps3p induces Toll-like receptor 2 signaling. J. Neuroinflammation 2008, 5:30.
49. Fox J.M., Letellier E., Oliphant C.J., Signoret N. TLR2-dependent pathway of heterologous down-modulation for the CC chemokine receptors 1, 2, and 5 in human blood monocytes. Blood 2011, 117:1851-1860.